Phase III, Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Summary
The purpose of this phase III study is to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel for front line treatment of locally-advanced pancreatic adenocarcinoma. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
General Information
NCT#: NCT03377491
Study ID: EF-27, PANOVA-03
Trial Phase: Phase III
Trial Sponsor: NovoCure Ltd.
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Tumor Treating Fields (TTFields)